A Molecular Framework for Delirium
- PMID: 38666272
- PMCID: PMC11040633
- DOI: 10.1177/19418744231207925
A Molecular Framework for Delirium
Abstract
Over 2.6 million adults over the age of 65 develop delirium each year in the United States (US). Delirium is associated with a significant increase in mortality and the US health care costs associated with delirium are estimated at over $164 billion annually. Despite the prevalence of the condition, the molecular pathophysiology of delirium remains unexplained, limiting the development of pharmacotherapies. Delirious patients can be identified by prominent impairments in attention and working memory (WM), two cognitive domains that localize to the dorsolateral prefrontal cortex (dlPFC). The dlPFC is also a key site for Alzheimer's disease (AD) pathology, and given the high risk of delirium in AD patients, suggests that efforts at understanding delirium might focus on the dlPFC as a final common endpoint for cognitive changes. Preclinical studies of the dlPFC reproduce many of the pharmacological observations made of delirious patients, including sensitivity to anticholinergics and an 'inverted U' pattern of dependence on monoaminergic input, with diminished performance outside a narrow range of signaling. Medications like guanfacine, which influence the dlPFC in the context of attention-deficit/hyperactivity disorder (ADHD), have emerged as therapies for delirium and motivate a detailed understanding of the influence of α-2 agonists on WM. In this review, I will discuss the neural circuitry and molecular mechanisms underlying WM and the function of the dlPFC. Localizing the cognitive deficits that are commonly seen in delirious patients may help identify new molecular targets for this highly prevalent disease.
Keywords: attention; cyclic adenosine monophosphate; delirium; dexmedetomidine; dorsolateral prefrontal cortex; guanfacine; hyperpolarization-activated cyclic nucleotide–gated channels; tetratricopeptide-repeat containing, Rab8b-interacting protein; working memory.
© The Author(s) 2023.
Conflict of interest statement
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Similar articles
-
Dorsolateral Prefrontal Cortex GABA Concentration in Humans Predicts Working Memory Load Processing Capacity.J Neurosci. 2016 Nov 16;36(46):11788-11794. doi: 10.1523/JNEUROSCI.1970-16.2016. J Neurosci. 2016. PMID: 27852785 Free PMC article.
-
Scientific rationale for the use of α2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders.Mol Psychiatry. 2023 Nov;28(11):4540-4552. doi: 10.1038/s41380-023-02057-4. Epub 2023 Apr 7. Mol Psychiatry. 2023. PMID: 37029295 Free PMC article. Review.
-
Comparison of transcranial brain stimulation approaches: prefrontal theta alternating current stimulation enhances working memory performance.Front Psychiatry. 2023 Jun 30;14:1140361. doi: 10.3389/fpsyt.2023.1140361. eCollection 2023. Front Psychiatry. 2023. PMID: 37457770 Free PMC article.
-
Transcranial Stimulation of the Dorsolateral Prefrontal Cortex Prevents Stress-Induced Working Memory Deficits.J Neurosci. 2016 Jan 27;36(4):1429-37. doi: 10.1523/JNEUROSCI.3687-15.2016. J Neurosci. 2016. PMID: 26818528 Free PMC article. Clinical Trial.
-
Mechanisms underlying dorsolateral prefrontal cortex contributions to cognitive dysfunction in schizophrenia.Neuropsychopharmacology. 2022 Jan;47(1):292-308. doi: 10.1038/s41386-021-01089-0. Epub 2021 Jul 20. Neuropsychopharmacology. 2022. PMID: 34285373 Free PMC article. Review.
References
-
- American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association, 2013. DOI: 10.1176/appi.books.9780890425596. - DOI
-
- Delirium RME. Hospitalized older adults. N Engl J Med. 2017;377:1456-1466.in - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources